Trial Profile
CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary)
- Indications Carcinoma; Uterine cancer
- Focus Therapeutic Use
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.
- 20 Sep 2017 New trial record